332
Views
12
CrossRef citations to date
0
Altmetric
Letter to the Editor

Comments on Initial experience with teriparatide in the United States

, , &
Page 1927 | Accepted 04 Aug 2006, Published online: 29 Aug 2006

References

  • Gold DT, Pantos BS, Masica DN, et al. Initial experience with teriparatide in the United States. Curr Med Res Opin 2006;22:703–8
  • Tashjian AH, Jr, Gagel RF. Teriparatide [human PTH(1–34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21: 354–65
  • Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1–34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312–21
  • Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426–38
  • Tashjian AH, Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;17: 1151–61
  • Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 6.1.4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.